Nilotinib(AMN-107)|Bcr-Abl kinase inhibitor,selective|CAS# 641571-10-0

Home >> Signaling Pathways >> TGF-β / Smad Signaling >> Bcr-Abl >> Nilotinib(AMN-107)

Size	Price	Stock
100mg	$50.00	In stock
250mg	$70.00	In stock
500mg	$120.00	In stock
1g	$179.00	In stock

Publications citing ApexBio Products

Nature.
2016 Apr 21;532(7599):398-401.

Nature.
2015 Aug 20;524(7565):309-14.

Cell.
2015 Aug 27;162(5):987-1002.

Cell.
2015 Feb 12;160(4):729-44.

Immunity.
2016 Jan 19;44(1):88-102

Nat Cell Biol.
2015 May;17(5):627-38.

Nat Neurosci.
2015 Oct;18(10):1464-73.

Nat Commun.
2016 Feb 1;7:10492.

J Cell Biol.
2016 Apr 11;213(1):109-25.

Cell Host Microbe.
2016 Jul 13;20(1):13-24.

Proc Natl Acad Sci U S A.
2016 Mar 8;113(10):2585-90.

Proc Natl Acad Sci U S A.
2015 Jun 30;112(26):E3365-73.

Proc Natl Acad Sci U S A.
2015 Jul 28;112(30):9412-7.

Autophagy.
2016 Jul 2;12(7):1129-52.

Cancer Res canres.
2946.2015.

Elife.
2016 Jan 14;5. pii: e12203.

Nucleic Acids Res.
2016 Feb 18;44(3):e2.

EMBO Rep.
2015 Sep;16(9):1114-30.

Oncogene.
2016 Mar 21.

Cell Rep.
2015 Sep 29;12(12):1986-96.

Cell Death Differ.
2016 Jun;23(6):1026-37.

Cell Death Differ.
2016 Jan;23(1):76-88.

Diabetes Obes Metab.
2015 Apr;17(4):403-13.

Oncotarget.
2015 Jan 20;6(2):1171-89.

J Neurosci.
2015 Sep 23;35(38):13244-56.

Sci Signal.
2014 Dec 23;7(357):ra122.

Mol Ther.
2015 Sep;23(9):1475-85.

J Nucl Med.
2016 Feb;57 Suppl 1:75S-80S.

Cardiovasc Res.
2015 Apr 1;106(1):153-62.

Cell Mol Life Sci.
2015 Nov;72(22):4399-407.

Anal Chem.
2015;87(10):5046-9.

Cancer Lett.
2016 Apr 28;374(1):1-11.

Quality Control

Quality Control & MSDS

View current batch:

Purity = 99.43%

Chemical structure

Related Biological Data

Histograms represent stereological quantiﬁcation of TDP-43 expressing cells. Asterisks indicate signiﬁcantly different to control or as indicated, mean + SEM, n=8, ANOVA, Neumann–Keuls multiple comparison.

Related Biological Data

Biological Activity

Description	Nilotinib (AMN-107) is an inhibitor of Bcr-Abl with IC50 less than 30 nM.
Targets	Bcr-Abl
IC50	30 nM

Protocol

Cell experiment: [1]
Cell lines	CD34+ cells from individual patients with CML
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.
Reacting condition	5 μM, 16 hours
Applications	After 16 hours in culture with nilotinib, long enough for inhibition of CrkL phosphorylation but not for induction of apoptosis, the total CD34+ cell samples studied exhibited only partial and variable inhibition (range, 49% to 0% inhibition) of CrkL phosphorylation.
Animal experiment: [2]
Animal models	C57Bl/6J mice injected with 8093 lymphoma cells
Dosage form	Oral administration, 75 mg/kg, daily
Application	Vehicle treated mice became moribund within 3 weeks of the transplantation. They showed clear symptoms of ALL. Nilotinib-treated mice lived statistically significantly longer as compared with the vehicle-treated mice. This result clearly indicated that nilotinib was very effective in inhibiting the proliferation of the leukemic cells in vivo.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1] Jørgensen H G, Allan E K, Jordanides N E, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 2007, 109(9): 4016-4019. [2] Kaur P, Feldhahn N, Zhang B, et al. Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer, 2007, 6(10): 67-77.

Nilotinib(AMN-107) Dilution Calculator

calculate

Nilotinib(AMN-107) Molarity Calculator

calculate

Chemical Properties

Cas No.	641571-10-0	SDF	Download SDF
Synonyms	AMN-107; Tasigna; AMN107
Chemical Name	4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
Canonical SMILES	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5
Formula	C₂₈H₂₂F₃N₇O	M.Wt	529.53
Solubility	Soluble in DMSO > 10 mM	Storage	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

Background

Nilotinib is a selective, oral inhibitor of tyrosine kinase with IC50 values of 20, 42, 31, 38, 29 and 41 nM for the autophosphorylation of native BCR-ABL (WT p210) and mutant BCR-ABL (E281K, E292K, F317L, M351T and F486S), respectively [1].

Nilotinib was designed based on the structure of imatinib and showed the superiority over imatinib in newly diagnosed or imatinib-resistant chronic myelogenous leukemia (CML). It was more potent than imatinib to wild-type BCR-ABL in a wide range of CML-derived and transfected cell lines. Nilotinib was also efficacious in gastrointestinal stromal tumors. Nilotinib showed inhibition activities in KIT mutant cells, including KITV560del, KITK642E and KITV560G (IC50 value of 108 nM). It also was effect to double mutations of KIT, such as KITV560del/V654A, KITV559D/D820Y, KITV560del/V654A (IC50: 192 nM) and KITV559D/D820Y (IC50: 297 nM). Besides that, Nilotinib exerted selective inhibition of PDGFRα and PDGFRβ. It suppressed cell proliferation with IC50 value of 0.54 nM in EOL-1 cells with constitutive activation of FIP1L1-PDGFRα [1, 2].

References:
[1] Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British Journal of Cancer, 2006, 94(12): 1765-1769.
[2] Blay J Y, Von Mehren M. Nilotinib: a novel, selective tyrosine kinase inhibitor//Seminars in oncology. WB Saunders, 2011, 38: S3-S9.